Navigation Links
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
Date:11/6/2007

BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November 2-6 in Boston, Mass.

-- Abstract (#91), "Interim results of Randomized Controlled Trial of

ELAD(R) in Acute on Chronic Liver Disease," was presented in a

parallel session on Monday, November 5th. This controlled, randomized

(2:1) clinical trial enrolled 69 patients with acute-on-chronic liver

failure in two protocols at two centers in Beijing, China. The first

49 patient protocol resulted in a 30 day transplant-free survival rate

of 50% in the controls and 87% in the treated group (p<0.01). The

second protocol, which had a shorter ELAD(R) treatment time, did not

reach statistical significance. Initial conclusions from this trial

demonstrated ELAD(R) is safe and effective in this patient population

when used with the longer treatment time.

-- Abstract (#855), "ELAD(R) Cellular and System Performance

Improvements," was a poster presentation detailing the metabolic

characteristics of the ELAD(R) cartridges in order to optimize

performance.

Terry Winters, Ph.D., Chairman and CEO said, "These data are consistent with our previous research and experience. ELAD is helping patients and the technology continues to be refined for optimum benefit. These are positive developments as we apply for marketing approval in China and advance our U.S. clinical program."

To date, only liver transplantation has been shown to increase survival. However, demand for liver transplantation far exceeds the supply of donor livers, creating a need for an alternative, lifesaving therapy such as ELAD(R). In China alone, an estimated 160 million people suffer from chronic liver infections such as Hepatitis B and C.

About ELAD(R) (Extracorporeal Liver Assist Device)

The ELAD(R) system provides important metabolic support for patients with liver failure, enabling a bridge-to-transplant or recovery, depending on the type and severity of liver disease. The system consists of four cartridges containing cells that function like normal human liver hepatocytes. The cells metabolize toxins and remove waste products while delivering essential proteins into the plasma. These cartridges are incorporated into a blood pumping system at the patient's bedside and enable continuous treatment for up to 12 days. The key to ELAD's(R) performance is a proprietary human hepatocyte cell line that can be grown, stored and shipped worldwide.

About Vital Therapies. Inc.

Vital Therapies, Inc. is a private San Diego-based liver therapy company that was founded in 2003. It is developing the first human liver cell-based system which provides important metabolic support for patients with severe liver failure. The company's manufacturing facility meets cGMP specifications to produce ELAD cartridges for patient treatment.

For more information, please visit VTI's Website at http://www.vitaltherapies.com


'/>"/>
SOURCE Vital Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Finally, a bruise cream that really works. Originally ... incorporated into the post-surgical treatment plans of a variety of other procedures including, but ... very effective for bruising and causes a rapid resolution of bruising and inflammatory changes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Markarian, DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission ... at the Gateway Convention Center in Collinsville. , They expect to ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
(Date:6/23/2016)... Colo., USA (PRWEB) , ... June 23, 2016 ... ... and Sanquin Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion research ... of patient enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score ...
(Date:6/23/2016)... ... June 23, 2016 , ... vcfo, a consulting firm that ... to announce the promotion of Mike Mackey to Regional Vice President of Southeast ... was responsible for managing client projects and overseeing vcfo financial consultants in the ...
Breaking Medicine News(10 mins):